Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Completed 3Terminated 2Recruiting 2Withdrawn 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1Inflammation 1Fatigue 1Colorectal Neoplasms 1Cognitive Dysfunction 1Behavior 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Riluzole × Clear all
NCT04761614 2025-03-28

Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
13 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00866840 2024-01-19

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase 2 Completed
13 enrolled 11 charts
Dermatologic

Melanoma

NCT02796755 2021-04-14

Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation

Emory University

Phase 4 Completed
30 enrolled 10 charts

Behavior, Fatigue, Inflammation, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡